Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Fat Loss and Metabolism

SURVODUTIDE

A dual GLP-1 + glucagon receptor agonist. The GLP-1 side curbs appetite like semaglutide; the glucagon side raises energy expenditure and targets liver fat, it’s being developed primarily for fatty-liver disease (MASH).

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

A dual GLP-1 + glucagon receptor agonist.

The GLP-1 side curbs appetite like semaglutide; the glucagon side raises energy expenditure and targets liver fat, it’s being developed primarily for fatty-liver disease (MASH).

What It Does

Survodutide activates both the GLP-1 receptor (satiety, slowed gastric emptying) and the glucagon receptor (increased energy expenditure, hepatic fat mobilization).

The glucagon component adds a metabolic-rate effect on top of appetite suppression.

Once-weekly.

Investigational; titrate carefully.

Reconstitution

Vial SizeBAC Water / SolventConcentration
10 mg+ 2 mL5 mg/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

PhaseFrequencyAmountNotes
Weeks 1–4Once0.6 mgIntro phase, adapt to dual GLP-1 + glucagon stimulation. weekly
Weeks 5–8Once1.2–2.4Step up only if well tolerated.
Weeks 9–16Once3.6–4.8Target range. 4.8 mg/week is the trial target.
MaintenanceOnce4.8–64.8 mg = Phase 2 target (NCT04667377); 6 mg = Phase 3 SYNCHRONIZE max. Do not exceed 6 mg,
Cycle & Timing

titrate over 14–20 weeks; the glucagon component makes nausea more likely than pure GLP-1, so go slowly.

Timing

same day each week, any time. Note: generally harsher on GI than mazdutide, don’t rush the ladder.

Population Considerations

Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises total testosterone, SHBG and gonadotropins as weight drops, and improves sperm and erectile function; and preserves fertility, unlike TRT (which suppresses spe Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises total testosterone, SHBG and gonadotropins as weight drops, and improves sperm and erectile function; and preserves fertility, unlike TRT (which suppresses sperm).

Handling & Stacking

Injection site
SubQ, abdomen/thigh. Rotate.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F.
  • Best used within ~3–4 weeks, kept cold (structure-based estimate, no published data); that is close to the 28- day sterility limit, so use whichever comes first.
Side effects
Nausea, vomiting, diarrhea, decreased appetite, elevated heart rate (glucagon effect). GI effects dose-dependent.
What to expect
Appetite suppression + a metabolic-rate bump; weight and liver-fat drop over months. Investigational. Supply math 10mg → 5 vials (16-wk titration toward 4.8 mg/wk)
Pairs well with
Lipo-C / L-Carnitine (metabolic support)
Avoid
Personal/family history of medullary thyroid carcinoma or MEN2. Prior pancreatitis. Pregnancy. Stacking with other incretins

Safety & Patient Education

Contraindications
Personal/family history of medullary thyroid carcinoma or MEN2 (GLP-1 class warning) Prior pancreatitis Pregnancy and lactation Severe gastroparesis
Warnings
Thyroid C-cell tumor signal in rodents (GLP-1 class) Gallbladder disease with rapid weight loss Elevated heart rate from glucagon agonism Possible small glucose elevation from glucagon, monitor in diabetics Investigational compound, no long-term human safety outside trials
Drug interactions
Insulin / sulfonylureas: hypoglycemia risk, adjust and monitor Delayed gastric emptying alters oral drug absorption Other GLP-1 agents: do not combine
Labs
  • Fasting glucose / HbA1c (baseline + periodic) Liver enzymes (often the point of therapy, track ALT/AST) Lipase if pancreatitis suspected; renal function with GI losses Resting heart rate / blood pressure Out of range?
  • Rising glucose/HbA1c = sugar creeping up; rising ALT/AST = liver stress (often the point of therapy, track the trend).
Stop criteria
Severe persistent abdominal pain (pancreatitis) Persistent vomiting / dehydration Sustained tachycardia or palpitations Pregnancy
Patient education
The glucagon component adds GI harshness and can raise heart rate, titrate slowly
References
researchdosing · peptidedosages · PubMed · clinicaltrials.gov · GLP-1 sex differences · Jensterle 2020